WHA President-Elect Announcement

Dear colleagues,   

I am delighted to announce that after a comprehensive and competitive selection process, Rachel Halford has been selected by the World Hepatitis Alliance (WHA) global board to serve as president-elect beginning January 2023.   

Rachel is the CEO of The Hepatitis C Trust and works at both an operational and strategic level across the UK. She has been the Executive Board Member for the European Region of the World Hepatitis Alliance for over two years and is a founding board member of Liver Patients International.  Passionate about equality and human rights Rachel has also led other non-governmental organisations, including Women in Prison Ltd; a national UK campaign that provides support and advocacy for women affected by the criminal justice system. She has over 24 years’ experience of working with people at high-risk of viral hepatitis, including homeless people, prisoners, substance users and migrants, as well as working across liver disease more generally.  

Diagnosed in 1998, Rachel cleared hepatitis C in 2007 following a year of Interferon treatment. Rachel’s extensive knowledge and experience of WHA and its activities started in 2015 when she attended the first World Hepatitis Summit in Glasgow, Scotland. She had just joined The Hepatitis C Trust as Deputy CEO working alongside the first WHA president Charles Gore.   

Rachel has demonstrated a bold vision for WHA and hepatitis elimination that we believe will propel our mission to “harness the power of people living with viral hepatitis to achieve its elimination.” In all her previous roles she has advocated for marginalised and underserved groups, lobbying governments and bringing about national and global change.  

Over the next year as Rachel serves as president-elect, she and I will work closely together to prepare her for the presidency and to assure a smooth transition. Together with our board and the staff team, we will strengthen WHA’s position on the global stage, use our voice to empower the millions living with viral hepatitis and help make the WHA mission a reality.   

Please join me in congratulating Rachel Halford on her appointment and welcoming her aboard! 

Danjuma Adda , WHA President

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close